Abstract
Advances in brain MRI have enabled many discoveries in neuroscience. Comparison of brain MRI features between cases and controls have highlighted potential causes of psychiatric and behavioral traits. However, due to the cost of collecting MRI data and the difficulty in recruiting particular patient groups, most studies have small sample sizes, limiting their reliability. Furthermore, interpretation is complicated by reverse causality, where many observed brain differences are the result of disease rather than the cause. Here we propose a method (BrainXcan) that leverages the power of large-scale genome-wide association studies (GWAS), reference brain MRI data, and methodological advances in causal inference using genetic instruments to discover new mechanisms of disease etiology and validate existing ones. BrainXcan tests complex traits for association with genetic predictors of brain MRI derived phenotypes to pinpoint relevant region-specific and cross-brain features. It also evaluates consistency and direction of the causal flow with Mendelian Randomization. As this approach requires only genetic data, BrainXcan allows us to test a host of hypotheses on mental illness, across many disorders and MRI modalities, using existing public data resources. Our method shows that reduced axonal density across the brain is associated with the risk of schizophrenia, consistent with the disconnectivity hypothesis. We also find structural features hippocampus, amygdala, and anterior cingulate cortex among others associated with schizophrenia risk highlighting the potential of our approach to bring orthogonal lines of evidence to inform the biology of complex traits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
YL, OM, and HKI received partial funding from P30DK020595, U01HG009086.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study was determined to be nonhuman subject but the University of Chicago's IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available in https://github.com/hakyimlab/brainxcan and links therein
